For many companies, artificial intelligence has become a key tool in drug development. Now, two companies that specialize in AI-backed drug development are teaming up to take on the rare disease known as Duchene Muscular Dystrophy. Rockville, Maryland-based Insilico Medicine and A2A Pharmaceuticals, Inc. joined forces on a new venture called Consortium.AI. The new company will use artificial intelligence to advance discovery of small molecules for the treatment of DMD and other orphan diseases. The startup said, "computationally pre-optimized new drug candidates have already been designed for targets validated through Insilico's artificial intelligence system."
Jul-23-2018, 12:56:07 GMT